We are here for you during the COVID-19 pandemic. Discover ways to protect yourself. Coronavirus & MesotheliomaWe are here for you during the COVID-19 pandemic. Discover ways to protect yourself.Explore Now

Menu

Request a Free Mesothelioma Information Guide

  • Information on top doctors and cancer centers
  • The latest clinical trials and treatment methods
  • Financial information to help with treatment costs
Request a Free Guide

Provided below is a list of the clinical trials that are currently in progress to evaluate new mesothelioma treatment protocols. Please note that the enrollment period for the following mesothelioma studies has concluded and no new participants are being recruited at this time.

The purpose of these studies is to determine both the safety and effectiveness of new mesothelioma drugs and treatment therapies. Click on a link to learn more about a study and to get recent update information.

Pembrolizumab in Treating Patients With Malignant Mesothelioma


Conditions: Mesothelioma, Lung Neoplasms

Last Updated: April 27, 2020

Status: Active, not recruiting

CAR T Cells in Mesothelin Expressing Cancers


Conditions: Adenocarcinoma, Mesothelioma, Fallopian Tube Neoplasms, Adenocarcinoma of Lung

Last Updated: April 23, 2020

Status: Active, not recruiting

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Lung Neoplasms

Last Updated: April 23, 2020

Status: Active, not recruiting

CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma


Conditions: Mesothelioma

Last Updated: April 20, 2020

Status: Active, not recruiting

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies


Conditions: Neoplasms

Last Updated: April 17, 2020

Status: Active, not recruiting

Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma


Conditions: Mesothelioma

Last Updated: April 17, 2020

Status: Active, not recruiting

Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53


Conditions: Neoplasms

Last Updated: March 18, 2020

Status: Active, not recruiting

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma


Conditions: Mesothelioma

Last Updated: March 16, 2020

Status: Active, not recruiting

Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion


Conditions: Mesothelioma, Pleural Effusion, Malignant, Pleural Effusion

Last Updated: March 12, 2020

Status: Active, not recruiting

Clinical and Histopathologic Characteristics of BAP1 Mutations


Conditions: Melanoma, Carcinoma, Renal Cell, Mesothelioma, Cholangiocarcinoma, Uveal Neoplasms

Last Updated: March 2, 2020

Status: Active, not recruiting

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.


Conditions: Neoplasms

Last Updated: February 26, 2020

Status: Active, not recruiting

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma


Conditions: Mesothelioma

Last Updated: February 25, 2020

Status: Active, not recruiting

Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients


Conditions: Mesothelioma

Last Updated: February 11, 2020

Status: Active, not recruiting

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma


Conditions: Mesothelioma

Last Updated: February 6, 2020

Status: Active, not recruiting

A Study of LY3023414 in Participants With Advanced Cancer


Conditions: Mesothelioma, Neoplasms

Last Updated: February 3, 2020

Status: Active, not recruiting

Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma


Conditions: Vaccinia, Mesothelioma, Pleural Effusion, Malignant, Pleural Effusion

Last Updated: January 17, 2020

Status: Active, not recruiting

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma


Conditions: Mesothelioma, Lung Neoplasms

Last Updated: January 14, 2020

Status: Active, not recruiting

Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma


Conditions: Mesothelioma, Lung Neoplasms

Last Updated: January 2, 2020

Status: Active, not recruiting

Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies


Conditions: Lung Neoplasms, Small Cell Lung Carcinoma, Mesothelioma

Last Updated: December 18, 2019

Status: Active, not recruiting

Diadem to Investigate the Activity and Safety of Durvalumab


Conditions: Mesothelioma

Last Updated: October 3, 2019

Status: Active, not recruiting

Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.


Conditions: Mesothelioma

Last Updated: August 2, 2019

Status: Active, not recruiting

PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma


Conditions: Mesothelioma

Last Updated: July 19, 2019

Status: Active, not recruiting

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma


Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma

Last Updated: June 19, 2019

Status: Active, not recruiting

Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134


Conditions: Mesothelioma

Last Updated: May 9, 2019

Status: Active, not recruiting

Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma


Conditions: Mesothelioma

Last Updated: May 7, 2019

Status: Active, not recruiting

A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas


Conditions: Lymphoma

Last Updated: May 3, 2019

Status: Active, not recruiting

Vinorelbine in Mesothelioma


Conditions: Mesothelioma

Last Updated: April 29, 2019

Status: Active, not recruiting

Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma


Conditions: Mesothelioma

Last Updated: March 29, 2019

Status: Active, not recruiting

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent


Conditions: Mesothelioma

Last Updated: February 11, 2019

Status: Active, not recruiting

Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma


Conditions: Mesothelioma

Last Updated: October 31, 2018

Status: Active, not recruiting

Dasatinib in Resectable Malignant Pleural Mesothelioma


Conditions: Mesothelioma

Last Updated: September 26, 2018

Status: Active, not recruiting

Written by

Linda Molinari Editor in Chief

Linda Molinari has more than 15 years of experience as a writer and advocate for mesothelioma patients and a ban on asbestos.


Full Bio Editorial Guidelines
Reviewed By

Annette Charlevois Patient Support Coordinator

Annette Charlevois is a senior paralegal at the law firm of Early, Lucarelli, Sweeney & Meisenkothen, helping patients find medical and legal resources.


Full Bio
Icon for

Get Help Contacting


    Privacy policy: All information is secure and will never be released

    TRUSTe

    Free

    Mesothelioma Treatment Guide

    Please fill in the form to request our FREE Mesothelioma Treatment Guide.
    It will be sent to you within 24 hours.

    Free Mesothelioma Treatment Guide



      Privacy policy: All information is secure and will never be released

      TRUSTe